Sareum Holdings plc (SAR.L) Research

Sareum Holdings plc operates as a specialized pharmaceutical company, primarily focused on discovering and advancing innovative therapeutic compounds for treating both cancer and autoimmune conditions. The firm develops small-molecule drugs, utilizing its proprietary Sareum Kinase Inhibitor Library as its core drug discovery platform. Its development portfolio currently features programs targeting Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. Sareum has also forged strategic partnerships with the Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. Founded in 2003, the company is headquartered in Cambridge, United Kingdom.

Market snapshot

Symbol
SAR.L
Price
$21.50
Day change
0.00%
Market cap
$29.8M
P/E ratio
-5.91x
52-week range
9.5-29
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 4 months

Peer companies

  • Aptamer Group plc (APTA.L)
  • Arecor Therapeutics plc (AREC.L)
  • Cambridge Cognition Holdings Plc (COG.L)
  • Fusion Antibodies plc (FAB.L)
  • Genflow Biosciences plc (GENF.L)
  • Inspiration Healthcare Group plc (IHC.L)
  • IXICO plc (IXI.L)
  • OptiBiotix Health Plc (OPTI.L)

Open Sareum Holdings plc (SAR.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.